Bevacizumab (avastin)

American Journal of Neuroradiology

Volumn 31, Issue 2, 2010, Pages 235-236

  Mukherji, Suresh K ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB;

ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; BLEEDING; BRAIN DISEASE; BREAST CANCER; COLORECTAL CANCER; DRUG COST; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG TARGETING; GLIOBLASTOMA; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LUNG CANCER; NOSE SEPTUM PERFORATION; PROSTATE CANCER; REVIEW;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 76749113881     PISSN: 01956108     EISSN: None     Source Type: Journal    
DOI: 10.3174/ajnr.A1987     Document Type: Review

References (12)

1. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004;25:581-611
2. Genentech, Inc. United States Securities and Exchange Commission. http://www.sec.gov/Archives/edgar/data/318771/000031877109000003/form10-k-2008. htm. Accessed October 6, 2009
3. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005;23:1011-27
4. Bevacizumab. Wikipedia. http://en.wikipedia.org/wiki/Bevacizumab. Accessed October, 6, 2009
5. Daniele G, Marciano R, Tortora G. The role of bevacizumab in breast cancer. Eur J Cancer 2008;6(suppl):26-29
6. Mukhopadhyay D, Datta K. Multiple regulatory pathways of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) expression in tumors. Semin Cancer Biol 2004;14:123-30
7. Presta LG, Chen H, O'Connor SJ, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997;57:4593-99
8. Yuan F, Chen Y, Dellian M, et al.. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci U S A 1996;93:14765-70
9. Willett CG, Boucher Y, di Tomaso E, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004;10:145-47
10. Gerber HP, Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 2005;65:671-80
11. Borgström P, Hillan KJ, Sriramarao P, et al. Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: novel concepts of angiostatic therapy from intravital videomicroscopy. Cancer Res 1996;56:4032-39
12. Borgström P, Bourdon MA, Hillan KJ, et al. Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo. Prostate 1998;35:1-10